1 min read
Purple Biotech Posts $0.51 Third-Quarter GAAP Loss Per Share
The company held $5.1 million in cash, cash equivalents and short-term deposits as of Sept. 30, 2026, with a projected runway through late 2027.

Purple Biotech posted a GAAP loss of $0.51 per share for the third quarter. The company held $5.1 million in cash, cash equivalents and short-term deposits as of Sept. 30, 2026.
Management’s current estimates and operating plan project that the funds will provide a runway through late 2027.